Adverum Biotechnologies, Inc. (ADVM) is a publicly traded company in the Unknown sector. Across all available filings, 28 corporate insiders have executed 174 transactions totaling $14.4M, demonstrating a bearish sentiment with -$4.5M in net insider flow. The most recent transaction on Dec 9, 2025 involved a transaction of 4,288,949 shares valued at $15.3M.
No significant insider buying has been recorded for ADVM in the recent period.
No significant insider selling has been recorded for ADVM in the recent period.
Based on recent SEC filings, insider sentiment for ADVM is bearish with an Insider Alignment Score of 34/100 and a net flow of -$4.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Adverum Biotechnologies, Inc. (ADVM) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 28 insiders are actively trading ADVM stock, having executed 174 transactions in the past 90 days. The most active insider is L.l.c. Fhmlsp, (Executive), who has made 1 transactions totaling $15.3M.
Get notified when executives and directors at ADVM file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 9, 2025 | Fhmlsp, L.l.c. | Executive | Tender | 4,288,949 | $3.56 | $15.3M | Large |
| Dec 9, 2025 | Machado Patrick | Executive | Tender | 8,818 | $N/A | $0 | |
| Dec 9, 2025 | Mark L. Lupher, Jr. | Executive | Tender | 13,000 | $N/A | $0 | |
| Dec 9, 2025 | Paul Scopa James | Executive | Tender | 10,333 | $N/A | $0 | |
| Dec 9, 2025 | Svoronos Dawn | Executive | Tender | 5,000 | $N/A | $0 | |
| Dec 9, 2025 | M. Rubinstein Linda | Executive | Option Exercise | 48,750 | $4.20 | $204.8K | |
| Dec 9, 2025 | M. Rubinstein Linda | Executive | Tender | 61,150 | $N/A | $0 | |
| Dec 9, 2025 | M. Rubinstein Linda | Executive | Tender | 42,000 | $N/A | $0 | |
| Dec 9, 2025 | M. Rubinstein Linda | Executive | Award | 42,000 | $N/A | $0 | |
| Dec 9, 2025 | M. Rubinstein Linda | Executive | Tender | 8,125 | $N/A | $0 | |
| Dec 9, 2025 | Seyedkazemi Setareh | Executive | Tender | 88,332 | $N/A | $0 | |
| Dec 9, 2025 | Seyedkazemi Setareh | Executive | Tender | 8,125 | $N/A | $0 | |
| Dec 9, 2025 | Seyedkazemi Setareh | Executive | Award | 85,000 | $N/A | $0 | |
| Dec 9, 2025 | Seyedkazemi Setareh | Executive | Tender | 54,874 | $N/A | $0 | |
| Dec 9, 2025 | Gurses Ozden Rabia | Executive | Tender | 8,125 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Tender(U) | 19 | $15.3M | 45.0% |
Sale(S) | 41 | $9.4M | 27.8% |
Purchase(P) | 29 | $4.9M | 14.5% |
Payment(F) | 23 | $2.6M | 7.7% |
Exercise(M) | 18 | $1.7M | 5.0% |
Award(A) | 43 | $0 | 0.0% |
Other(J) | 1 | $0 | 0.0% |
Insider selling pressure at Adverum Biotechnologies, Inc. has increased, with 28 insiders executing 174 transactions across all time. Total sales of $9.4M significantly outpace purchases of $4.9M, resulting in a net outflow of $4.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.